Product logins

Find logins to all Clarivate products below.


Dyslipidemia | Treatment Algorithms: Claims Data Analysis | Hypertriglyceridemia | US | 2019

Hypertriglyceridemia is characterized by elevated triglyceride (TG) levels. In addition to lifestyle changes, current treatment focuses on improving patients’ TG levels with the aim to reduce the associated CV risk. Fibrates, statins, and omega-3 fatty acids are predominantly prescribed to manage hypertriglyceridemia patients. Using a longitudinal claims data analysis, we demonstrate how hypertriglyceridemia is being treated in the United States and provide insight into what is driving current prescribing practices for newly diagnosed and recently treated patients.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed hypertriglyceridemia patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed hypertriglyceridemia patients?
  • How has Vascepa been integrated into the hypertriglyceridemia treatment algorithm compared with the available generic omega-3 fatty acids?
  • What percentage of hypertriglyceridemia patients receive drug therapy within six months of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of hypertriglyceridemia patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated hypertriglyceridemia patients?

Geographies: United States

Real World Data: Longitudinal patient-level claims data analysis

Key Drugs Covered: Fibrates, omega-3-acid ethyl esters (Lovaza), Vascepa, statins, niacin derivatives

Key Analysis Provided

  • Brand/therapy usage across longitudinal patient sample
  • Newly diagnosed patient analysis
  • Treatment initiation and progression
  • Line of therapy analysis
  • Combination therapy analysis
  • Source of business for recently treated patients
  • Persistency and compliance analysis
  • Product-level patient flowcharts

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, so you can accurately assess your source of business, benchmark usage against competitors, and quantify areas of opportunity for your marketed or emerging brand.

Related Market Assessment Reports

Report
Painful Diabetic Neuropathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Painful Diabetic Neuropathy (US)
Painful diabetic neuropathy (PDN) is a prevalent complication of diabetes, typically causing persistent burning, tingling, or sharp pain in the extremities. Management relies on a range of…
Report
Bipolar Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Bipolar Disorder (US)
Bipolar disorder (BPD) is a chronic condition characterized by recurrent episodes of aberrant mood, with patients experiencing manic, depressive, or mixed symptoms between periods of stable mood…
Report
Type 1 Diabetes – Current Treatment – Treatment Algorithms: Claims Data Analysis – Type 1 Diabetes (US)
Intensive insulin regimens have proven effective in delaying the progression of complications associated with untreated or poorly treated type 1 diabetes (T1D). Thus, insulins remain the…
Report
Rheumatoid Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Rheumatoid Arthritis (US)
The treatment of rheumatoid arthritis (RA) typically begins with cost-effective conventional DMARDs (cDMARDs) such as methotrexate or hydroxychloroquine. For patients who fail cDMARD treatment or…
Report
Migraine – Current Treatment – Treatment Algorithms: Claims Data Analysis – Acute Migraine (US)
Episodic and chronic migraines are often disabling and reduce patients’ quality of life. Despite triptans’ dominance in the treatment algorithm, many patients respond inadequately, cannot…